Jaguar Health (JAGX) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Jaguar Health is the larger company by market cap ($3.0 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAGX | MBIO |
|---|---|---|
| Share price | $0.227 | $0.3541 |
| Market cap | $3.03M | $2.69M |
| 1-day change | -30.58% | -4.30% |
| EPS (TTM) | $-257.15 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $11.51M | — |
| Revenue growth (YoY) | -1.52% | — |
| Net income (latest FY) | $-53.58M | $-1.92M |
| Gross margin | 67.21% | — |
| Operating margin | -398.82% | — |
| Net margin | -465.42% | — |
| 52-week high | $981.75 | $1.43 |
| 52-week low | $0.22 | $0.35 |
| Distance from 52-week high | -99.98% | -75.24% |
| Average volume | 2.40M | 33.87K |
| Shares outstanding | 13.35M | 6.74M |
| Employees | 47 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jaguar Health
JAGX stock →Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
JAGX vs MBIO FAQ
Which is bigger, Jaguar Health or Mustang Bio?
Jaguar Health (JAGX) is larger, with a market capitalization of $3.03M compared with $2.69M for Mustang Bio (MBIO).
Are Jaguar Health and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.